Trial reportHealth economics2022
Mapping between EQ-5D-3L and EQ-5D-5L: A survey experiment on the validity of multi-instrument data.
Trial report in Health economics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mapping to estimate health state utility: a systematic review of development and limitations.Health and quality of life outcomes · 2025Pooled it
- Mapping between EQ-5D-3L and EQ-5D-5L: A survey experiment on the validity of multi-instrument data.Health economics · 2022Trial
- The Feasibility and Acceptability of a Collaborative Deprescribing Intervention to Reduce Anticholinergic Burden Among Hospitalised Older Patients.Basic & clinical pharmacology & toxicology · 2026Article
- Article
- Article
- Mapping EQ-5D-5L Utilities in Dementia: Integrating Self and Proxy Reports.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2025Article
- Leber hereditary optic neuropathy: utilities and carer burden from British and Irish participants.Orphanet journal of rare diseases · 2025Article
- Cost-Effectiveness Analysis of Daridorexant for the Pharmacological Treatment of Chronic Insomnia Disorder in Adults.PharmacoEconomics - open · 2025Article
- Cost-effectiveness of Cerebrolysin as an add-on treatment for neurorecovery after traumatic brain injury.Journal of medicine and life · 2025Article
- Experience of living with psoriasis in Brazil: a Global Psoriasis Atlas online survey.International journal of dermatology · 2025Article
- The Burden of Adult X-Linked Hypophosphatemia on Carers and Family Members: A Mixed-Methods Study.Journal of health economics and outcomes research · 2025Article
- A Vignette Study to Derive Health-Related Quality-of-Life Weights for Individuals with Steroid Refractory Chronic Graft-versus-Host Disease Receiving Third-Line Therapy in the United Kingdom.Journal of health economics and outcomes research · 2025Article
- Psychometric Properties of the EQ-5D-5L in Patients with Alopecia Areata.PharmacoEconomics - open · 2024Article
- Article
- Estimating the Relationship Between EQ-5D-5L and EQ-5D-3L: Results from a UK Population Study.PharmacoEconomics · 2023Article
- Mapping the Insomnia Severity Index Instrument to EQ-5D Health State Utilities: A United Kingdom Perspective.PharmacoEconomics - open · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
EQ-5D is a 5-item questionnaire instrument designed to measure health-related quality of life. It is extremely important, since it is used to measure health benefits in many studies providing evidence for reimbursement decisions by the National Institute for Health and Care Excellence in England and similar policy bodies in other countries. EQ-5D has been redesigned in a more detailed form (EQ-5D-5L), but much existing cost-effectiveness evidence is based on the older version (EQ-5D-3L). Statistical mapping from one version to another is widely used, exploiting data from multi-instrument surveys incorporating both variants. However, little is known about the robustness of data from such multi-instrument surveys. We design a randomized experiment to investigate whether inclusion of both versions at different stages in a single interview gives a reliable picture of the relationship between health measures from the two instruments and embed it in individual interviews from the UK Understanding Society household panel. We find that sequencing of the two versions of EQ-5D within an interview has a significant impact not only on the resulting data but also on the estimated mapping models. We illustrate the non-negligible effects in two real-world cost-effectiveness examples and discuss the implications for future multi-instrument survey design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.